{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:07:52Z","timestamp":1787166472330,"version":"build-2736575974"},"reference-count":38,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Dupilumab is an effective long-term treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), but continuous biweekly (Q2W) treatment is associated with high costs, cumulative drug exposure, and treatment burden. Extending injection intervals may reduce these burdens. This real-world study aimed to evaluate the feasibility and clinical outcomes of dupilumab interval extension compared with continued standard Q2W dosing. Methods: In this retrospective single-center study, 35 adults with CRSwNP who had received dupilumab 300 mg Q2W for &gt;12 months underwent a stepwise interval-extension attempt (two-week increments, \u22656 months between steps) and were compared with 30 patients who continued Q2W dosing. Clinical outcomes were assessed every six months using the Sino-Nasal Outcome Test-22 (SNOT-22) and Nasal Polyp Score (NPS). Results: Of the 35 patients, 19 patients (54%) reached a dosing interval of Q4W or longer, and eight patients (23%) maintained a partial extension to Q3W after not tolerating Q4W. The remaining eight patients (23%) returned to Q2W. Thus, 27 patients (77%) stayed on an extended interval beyond the standard Q2W regimen, which was maintained throughout follow-up without reversion to a shorter regimen. SNOT-22 and NPS improved significantly after dupilumab initiation and remained stable throughout follow-up in both groups, with no significant between-group differences in longitudinal outcomes. No patient needed rescue treatments during follow-up. Conclusions: In selected clinically stable patients with CRSwNP, dupilumab interval extension appeared feasible and was associated with maintained disease. Individualized dose tapering, including intermediate intervals such as Q3W, may reduce treatment burden without compromising disease control. Larger prospective studies are needed to define optimal extension protocols and identify predictors of successful interval extension.<\/jats:p>","DOI":"10.3390\/ph19060961","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:06:34Z","timestamp":1782875194000},"page":"961","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extension of Dupilumab Injection Intervals in Chronic Rhinosinusitis with Nasal Polyps: A Real-World Study"],"prefix":"10.3390","volume":"19","author":[{"given":"Michael","family":"Habenbacher","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Moser","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0678-2850","authenticated-orcid":false,"given":"Ahmed","family":"Abaira","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0273-0793","authenticated-orcid":false,"given":"Jakob","family":"Pock","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lampl","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-9931","authenticated-orcid":false,"given":"Alexandros","family":"Andrianakis","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2500\/ajra.2013.27.3981","article-title":"Epidemiology and Differential Diagnosis of Nasal Polyps","volume":"27","author":"Chaaban","year":"2013","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/000348940311200709","article-title":"Prevalence of nasal polyps in adults: The Skovde population-based study","volume":"112","author":"Johansson","year":"2003","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41577-025-01159-0","article-title":"The immunology of asthma and chronic rhinosinusitis","volume":"25","author":"Kato","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J. Asthma. Allergy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15074","article-title":"Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches","volume":"77","author":"Kato","year":"2022","journal-title":"Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2022.02.016","article-title":"Mechanisms and pathogenesis of chronic rhinosinusitis","volume":"149","author":"Kato","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1007\/s00405-024-08832-5","article-title":"Patterns of recurrence in patients with CRSwNP who underwent complete FESS","volume":"281","author":"Levi","year":"2024","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Calvanese, L., Fabbris, C., Brescia, G., Di Pasquale Fiasca, V.M., Deretti, A., Finozzi, F., Franz, L., Frigo, A.C., and Marioni, G. (2024). Polyps\u2019 Extension and Recurrence in Different Endotypes of Chronic Rhinosinusitis: A Series of 449 Consecutive Patients. J. Clin. Med., 13.","DOI":"10.3390\/jcm13041125"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ACI.0000000000001146","article-title":"Biologics for chronic rhinosinusitis with nasal polyps: From downstream cytokine blockade to upstream epithelial targets","volume":"26","author":"Zahedi","year":"2026","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s00405-024-08725-7","article-title":"Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: A review of the literature","volume":"281","author":"Reale","year":"2024","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Habenbacher, M., Moser, U., Abaira, A., Kiss, P., Holzmeister, C., Pock, J., Walla, K., Lang, A., and Andrianakis, A. (2024). Investigation of Blood Count-Based Inflammatory Biomarkers as Predictors of Response to Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16111370"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaci.2024.10.016","article-title":"Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR)","volume":"155","author":"Seys","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40463-023-00668-z","article-title":"The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP)","volume":"52","author":"Hardison","year":"2023","journal-title":"J. Otolaryngol.-Head Neck Surg."},{"key":"ref_21","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11882-025-01214-9","article-title":"Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review","volume":"25","author":"Loperfido","year":"2025","journal-title":"Curr. Allergy Asthma. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/lary.32162","article-title":"Dupilumab Monthly Dose De-Escalation Maintains Efficacy in CRSwNP: A Two-Year Real-World Study","volume":"135","author":"Montuori","year":"2025","journal-title":"Laryngoscope"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months","volume":"78","author":"Otten","year":"2023","journal-title":"Allergy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00106-024-01487-y","article-title":"Chronic rhinosinusitis with nasal polyps-extension of dupilumab treatment intervals","volume":"72","author":"Appel","year":"2024","journal-title":"HNO"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1007\/s00405-025-09677-2","article-title":"Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: A real-world study from Saudi Arabia: Extended dupilumab dosing in CRSwNP","volume":"282","author":"Alghamdi","year":"2025","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.21053\/ceo.2024.00233","article-title":"Therapeutic Effectiveness of SNOT 22-Based Interdose Interval Adjustment of Dupilumab for Chronic Rhinosinusitis with Nasal Polyps","volume":"17","author":"Yoon","year":"2024","journal-title":"Clin. Exp. Otorhinolaryngol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Campion, N.J., Petsiou, D.P., Fally, F.C., Berbalk, K., Melamed, N.F., Tu, A., Morgenstern, C., Kidane, F.A., Zghaebi, M., and Liu, L. (2026). Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes. Int. Forum. Allergy Rhinol., Epub ahead of print.","DOI":"10.1002\/alr.70125"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1111\/all.16263","article-title":"Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3\u2009years","volume":"79","author":"Huber","year":"2024","journal-title":"Allergy"},{"key":"ref_30","first-page":"552","article-title":"Multi-institutional minimal clinically important difference of the 22-item Sinonasal Outcome Test in medically managed chronic rhinosinusitis","volume":"59","author":"Phillips","year":"2021","journal-title":"Rhinology"},{"key":"ref_31","first-page":"4","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2012","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"key":"ref_32","first-page":"287","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4193\/Rhin23.335","article-title":"Consensus criteria for chronic rhinosinusitis disease control: An international Delphi Study","volume":"61","author":"Sedaghat","year":"2023","journal-title":"Rhinology"},{"key":"ref_34","first-page":"38","article-title":"Development and psychometric validation of the Chronic Rhinosinusitis Control Test","volume":"64","author":"Cotter","year":"2026","journal-title":"Rhinology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/alr.70173","article-title":"Disease Remission: A Scoping Review with Thematic Analysis of the Scientific Literature with Implications for Chronic Rhinosinusitis","volume":"16","author":"Parail","year":"2026","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"ref_36","unstructured":"(2026, April 30). \u00d6sterreichische Sozialversicherung Infotool Zum Erstattungskodex. Available online: https:\/\/www.erstattungskodex.at."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"110316","DOI":"10.1016\/j.jpsychores.2020.110316","article-title":"Assessment of health-related quality-of-life in patients with chronic Rhinosinusitis\u2014Validation of the German Sino-Nasal Outcome Test-22 (German-SNOT-22)","volume":"140","author":"Gottfried","year":"2021","journal-title":"J. Psychosom. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.otohns.2006.09.014","article-title":"Rhinosinusitis: Developing guidance for clinical trials","volume":"135","author":"Meltzer","year":"2006","journal-title":"Otolaryngol. Head. Neck. Surg."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/961\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:31:24Z","timestamp":1782876684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060961"],"URL":"https:\/\/doi.org\/10.3390\/ph19060961","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}